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Abstract The Xenopus laevis oocyte expression system was
used to determine the activities of K-conotoxins EpI and the
ribbon isomer of AuIB, on de¢ned nicotinic acetylcholine recep-
tors (nAChRs). In contrast to previous ¢ndings on intracardiac
ganglion neurones, K-EpI showed no signi¢cant activity on oo-
cyte-expressed K3L4 and K3L2 nAChRs but blocked the K7
nAChR with an IC50 value of 30 nM. A similar IC50 value
(103 nM) was obtained on the K7/5HT3 chimeric receptor stably
expressed in mammalian cells. Ribbon AuIB maintained its se-
lectivity on oocyte-expressed K3L4 receptors but unlike in native
cells, where it was 10-fold more potent than native K-AuIB, had
25-fold lower activity. These results indicate that as yet uniden-
ti¢ed factors in£uence K-conotoxin pharmacology at native ver-
sus oocyte-expressed nAChRs.
0 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
To date eight K and three L subunits (K2^K7, K9, K10, L2^
L4) of the nicotinic acetylcholine receptor (nAChR) have been
cloned from sensory and neuronal mammalian cells. These
have the potential to assemble in a great diversity of nAChR
subtypes with di¡erent pharmacological and functional prop-
erties [1]. Numerous neuronal nAChR subtypes have been
identi¢ed in native tissues and in several cells the presence
of more than one subtype has been demonstrated. To deci-
pher the composition and function of the various nAChR
subtypes, selective ligands are needed to correlate the pharma-
cological properties of de¢ned heterologously expressed sub-
unit combinations with native receptors. K-Conotoxins, small
disul¢de-rich peptides from the venom of the predatory ma-
rine snails of the genus Conus, are amongst the most selective
inhibitors of nAChR subtypes to be identi¢ed [2] (Fig. 1).
Di¡erences in single channel conductance, kinetics and rel-
ative agonist potencies have been observed between heterolo-
gously expressed nAChRs and nAChRs characterised in na-
tive tissues [3] and even upon heterologous expression of the
same subunit combination in di¡erent expression systems dis-
tinct properties were observed [4]. In order to de¢ne struc-
ture^activity relations for the design of optimised synthetic
peptides, it is therefore important to compare activity data
generated in a common system.
Because of its highly reproducible and e⁄cient expression
and the apparent absence of endogenous nAChR subunits,
the Xenopus oocyte expression system is widely used to study
de¢ned subunit combinations of the nAChR. In fact, most
neuronal active K-conotoxins were initially characterised on
oocyte-expressed nAChR subtypes. Here we show that sub-
type selectivity of K-conotoxin EpI is switched from K3L2/
K3L4-selective to K7-selective in native versus oocyte-ex-
pressed receptors, respectively. In addition, signi¢cant di¡er-
ences in activity between two isomers of K-conotoxin AuIB
that act on the same receptor exist between native and oocyte-
expressed K3L4 receptors.
2. Materials and methods
2.1. Peptide synthesis
AuIB and its isomer were assembled on Boc-Phe-OCH2-Pam resin
using standard BOC-Chemistry, deprotected and cleaved from resin as
described previously [5]. The globular and ribbon isomers were
formed by oxidation of the fully reduced puri¢ed [reversed-phase
high-performance liquid chromatography (RP-HPLC)] peptide at a
concentration of 0.08 mg/ml in 20% isopropanol in 0.1 M NH4HCO3
(pH 8.0). A third isomer, most probably a beads isomer, formed in
very small amounts and was found to be unstable. The oxidised pep-
tides were puri¢ed by preparative RP-HPLC using a C18 Vydac col-
umn.
EpI and [Y15]EpI were made by Fmoc chemistry as described [6].
HPLC-puri¢ed reduced peptides (20 WM) were oxidised in 100 mM
ammonium bicarbonate at pH 7.5^8 with stirring for 24^48 h at room
temperature. The oxidised peptides were puri¢ed by preparative RP-
HPLC. Peptides were quanti¢ed initially in triplicate by amino acid
analysis, then subsequently by RP-HPLC using an external reference
standard for each peptide.
2.2. Functional characterisation
2.2.1. Plasmids and cRNA preparation. Plasmids containing
cDNA encoding rat K3, K4, K7, L2, and L4 nAChR subunits were
provided by J. Patrick (Baylor College of Medicine, Houston, TX,
USA) and subcloned into the oocyte expression vector pNKS2 [7].
0014-5793 / 03 / $22.00 I 2003 Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
doi:10.1016/S0014-5793(03)01161-X
*Corresponding author. Fax: (61)-7-3346 2101.
E-mail address: r.lewis@imb.uq.edu.au (R.J. Lewis).
1 Present address: Max Planck Institute for Experimental Medicine,
Hermann Rein-Str. 3, D-37075 Go«ttingen, Germany.
Abbreviations: nAChR, nicotinic acetylcholine receptor; ACh, acetyl-
choline; K-BTX, K-bungarotoxin
FEBS 27779 23-10-03
FEBS 27779 FEBS Letters 554 (2003) 219^223
cRNA was synthesised using the Message Machine kit (Ambion, Aus-
tin, TX, USA). cDNAs for chicken K7 and mouse 5HT3 subunits were
provided by M. Ballivet and D. Julius. The K7/5HT3 chimera was
constructed according to Eisele et al. [8] and cloned into the inducible
vector pcDNA4/TO [9].
2.2.2. Two-electrode voltage-clamp recording on oocyte-expressed
nAChRs. Oocytes were prepared and two-electrode voltage-clamp
recordings were performed as previously described [10]. cRNA-in-
jected oocytes were clamped at a holding potential of 370 mV and
acetylcholine (ACh)-activated membrane currents were recorded using
a two-electrode virtual ground circuit on a GeneClamp 500B ampli¢er
(Axon Instruments Inc., Union City, CA, USA), ¢ltered at 200 Hz
and digitised at 1 kHz using a Digidata 1322A interface and v8.2
Clampex software (Axon Instruments Inc.). The perfusion medium
was manually switched between ND96 (96 mM NaCl, 2 mM KCl,
1 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES at pH 7.4) with or
without agonist using a Valve Driver II (General Valve Corporation,
Fair¢eld, NJ, USA). A fast and reproducible solution exchange
(6 300 ms) for agonist application was achieved using a 50 Wl fun-
nel-shaped oocyte chamber combined with a fast solution £ow (V150
Wl/s) fed through a custom-made manifold mounted immediately
above the oocyte.
One WM ACh (Sigma) was used to activate K4L4 subunits, 100 WM
ACh was used to activate K3L2, K3L4 and K4L2 subunits, and 100 WM
nicotine (Sigma) was used to activate K7 nAChRs. Agonist pulses
were applied for 2 s in 4-min intervals. After each application, the
cell was superfused for 1 min and the £ow was then stopped until the
agonist was re-applied. Peptide was applied when responses to three
consecutive agonist applications di¡ered by less than 10%. After the
1-min agonist washout step was stopped, 5.5 Wl of a 10-fold-concen-
trated peptide solution were pipetted directly into the static bath,
mixed by repeated pipetting, and incubated for 3 or 5 min prior to
addition of agonist. Dose^response curves were ¢tted to the data by
the equation: % response= 100/{1+([toxin]/IC50)nH}, using Prism soft-
ware (GraphPad v 3.0 for Macintosh, San Diego, CA, USA).
2.2.3. Patch-clamp recordings on chimeric K7/5HT3 nAChRs. The
chimera K7/5HT3 was expressed in TRex-293 cells (Invitrogen) which
are derived from HEK293 cells. Expression of the K7/5HT3 chimera
was induced by the addition of tetracycline 24^48 h prior to experi-
ments. Whole-cell current recordings were performed, using an LM-
EPC-7 patch-clamp system (List, Darmstadt, Germany), on nAChR-
expressing HEK293 cells cultured 3 days on ¢bronectin-coated cover-
slips. The bathing solution was composed of (mM): NaCl 145; KCl
5; MgCl2 1; CaCl2 2; D-glucose 10; HEPES 10 (pH 7.3; 300 mOsm),
and the internal pipette solution contained (mM): CsCl 140 (equili-
brated with CsOH); EGTA 11; HEPES 10; MgCl2 1, (pH 7.3; 300
mOsm). The patch microelectrodes were made from borosilicate glass
(external diameter 1.6 mm), and the pipette resistance was measured
as 3^7 M6 when ¢lled with the internal solution. After formation of a
high-resistance seal with the cell membrane, capacitance transients
were minimised using the C-Fast facility of the system. No additional
capacitance and serial resistance compensation was applied. All ex-
periments were performed at room temperature at a holding potential
of 370 mV. Coverslips were incubated with 5 ml of bathing solution
with selected concentrations of EpI for 5 min. Then whole-cell cur-
rents of K7/5HT3 were induced by fast application of 3 WM nicotine
dissolved in external solution, using a U-shaped tube positioned near
the investigated cell, at a £ow rate of 1.0 ml/min. The agonist pulses
were for 2 s in 1-min intervals. Signals were ¢ltered at 3.15 kHz
(Bessel), digitised to 10 kHz and analysed on a PC using the pClamp
software package version 6.03 (Axon Instruments, Foster City, CA,
USA). Dose^response curves were ¢tted to the data by using Prism
software (GraphPad v 4.0 for Windows, San Diego, CA, USA).
3. Results and discussion
3.1. EpI switches subtype selectivity on oocyte-expressed versus
native nAChRs in intracardiac ganglia
EpI was originally characterised in dissociated neurones of
parasympathetic intracardiac ganglia, which are believed to
contain primarily K3L2* and K3L4* nAChRs (* indicates
the possible inclusion of further subunits [11]), and on bovine
chroma⁄n cells, a model for K3L4* nAChRs. EpI was found
to block K3L2* and K3L4* nAChRs but failed to inhibit an K-
bungarotoxin (BTX)-sensitive current believed to represent an
K7* receptor [6]. EpI shares the N-terminal eight amino acid
residues with the K7-selective K-conotoxin ImI (Fig. 1) and
comparison of their 3D structures showed identical structures
for the ¢rst loop [12]. To determine the selectivity of EpI and
to provide a common basis for comparison with other neuro-
nal active K-conotoxins, we determined EpI activity on de-
¢ned oocyte-expressed nAChRs. In contrast to previous ¢nd-
ings in the native systems [6], EpI showed no or very low
activity on oocyte-expressed K3L2 or K3L4 receptors. It
blocked, however, homomeric K7 receptors with an IC50 value
of 30 nM (Fig. 3, Table 1). Even 100 nM EpI, which caused a
75% block of the K7 receptor in the oocyte system, did not
inhibit the K-BTX-sensitive receptor in intracardiac ganglia
[6]. The non-sulphated analogue of EpI, which blocked the
native K3L4/K2L4 with slightly higher potency than EpI, was
three-fold less potent on oocyte-expressed K7 receptors (Fig.
3, Table 1).
The K-BTX-sensitive current in intracardiac ganglia shows
an unusually slow inactivation and rapid recovery from K-
BTX-block, in contrast to the ‘classical’ K7 current found
for example in chicken ciliary ganglions, PC12 cells and hip-
pocampus neurones [13]. Together with the lack of sensitivity
to EpI, this might indicate that another subunit than K7 ac-
counts for this current. However, the fact that an anti-K7
mAb selectively inhibited the K-BTX-sensitive current identi-
¢ed in intracardiac ganglia argues against this possibility, and
for the presence of an K7* nAChR with unusual kinetics [13].
Interestingly, an K7 splice variant (K7^2) recently identi¢ed in
intracardiac ganglia is able to form functional homomeric
channels that resemble the K-BTX-sensitive current in these
cells [14] and might account for the distinct K-conotoxin
pharmacology. Since EpI was able to inhibit currents that
were maximally inhibited by the K7-selective antagonists
[A10L]PnIA and K-BTX [15], the receptor targeted by EpI
in intracardiac ganglia is clearly di¡erent from known K7*
receptors.
3.2. Native AuIB and the ribbon isomer of AuIB switch relative
activities in oocyte-expressed versus native K3L4* nAChRs
in intracardiac ganglia
The lack of activity of EpI at oocyte-expressed K3L2 and
Fig. 1. Comparison of sequences and activity of EpI and AuIB and
other neuronal active K-conotoxins. Asterisks indicate C-terminal
amidation. Sulfated Tyr are underlined, Q= Q-carboxyglutamic acid,
and O=hydroxyproline. Note that PnIA, [A10L]PnIA, and PnIB
were originally synthesised and characterised as unsulphated pep-
tides, although the native toxins are sulphated.
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K3L4 nAChRs also suggests that the native receptors behave
signi¢cantly di¡erently to the oocyte-expressed receptors.
However, the K3L2-selective PnIA and the K3L4-selective
AuIB both inhibited the respective currents in oocytes and
in intracardiac ganglia and the reported IC50 values for
PnIA in intracardiac ganglia cells (14 nM) and on the oo-
cyte-expressed K3L2 combination (9.6 nM) are similar. This
indicates that at least K3L2* receptors have matching proper-
ties in oocytes and native tissues. In contrast, AuIB blocked
the current in intracardiac ganglia with an IC50 value of 1.2
nM [5], which is about 500-fold lower than the IC50 values of
750 nM [16] and 966 nM (this study) found in oocytes (Fig. 2,
Table 1). Surprisingly, ribbon AuIB, an isomer with the di-
sul¢de connectivity 1^4 and 2^3 instead of 1^3 and 2^4, was
even more active (IC50 0.1 nM) on the ganglia cells [5]. Its
IC50 value on oocyte-expressed K3L4 was 27.5 WM, about 30
times higher than that for native AuIB and even 3 000 000
times higher than that determined on native receptors
(Fig. 2, Table 1). The unexpected activity of the ribbon isomer
was explained by a higher structural £exibility of the molecule
possibly allowing a more complementary ¢t in the binding site
[5]. To check whether this could also change the subtype se-
lectivity, we tested ribbon AuIB on oocyte-expressed
nAChRs. Like native AuIB, 10 WM ribbon AuIB did not
cause signi¢cant inhibition of K3L2, K4L2, K4L4, and K7 re-
ceptors (data not shown). AuIB was originally identi¢ed on
oocyte-expressed receptors [16] (Fig. 1) and in various subse-
quent studies it was successfully used to de¢ne native K4L3*
nAChRs. The surprisingly large di¡erences in activity of AuIB
and its ribbon isomer found in this study suggest that the
supposed K3L4* nAChR in intracardiac ganglia di¡ers from
those in oocytes and other tissues, e.g. rat medial habenula
neurones and chick ciliary ganglion neurones, where similar
potencies as in the oocyte system were observed [17,18].
3.3. Do K3L4 and K7 subunits in intracardiac ganglia neurones
combine with other subunits?
A possible explanation for these inconsistent ¢ndings could
be that alternately transcribed isoforms or other combinations
than the assumed K3L2 and K3L4 receptors account for the
observed phenotype in native cells. A single-cell PCR study on
intracardiac ganglia neurones [19] revealed the presence of
eight di¡erent subunits (K2-K5, K7 and L2-L4) that were het-
erogenously expressed in nine examined cells. Overall, the K3,
L2, L4 and K7 subunits appeared to dominate whereas K2, K4
and L3 were only detected in one or two cells. The genes
encoding K3, K5, and L4 are clustered and heterologous ex-
pression of trimeric K3K5L2 and K3K5L4 combinations has
been described [20,21]. Therefore, the K3K5L4 combination
was expressed in oocytes to test whether the K5 subunit was
able to confer EpI sensitivity or the increased sensitivity to the
ribbon AuIB isomer. However, no di¡erences as compared to
the K3L4 combinations were found. Likewise, the K3K5L2
combinations did not show an altered EpI sensitivity (Fig. 3).
Although several studies indicate a homopentameric assem-
bly of native K7 receptors [22] there is also increasing evidence
for heteromeric K7 complexes and recently, the coassembly of
K7 and L2 receptors has been described [23]. To test whether
Table 1
Comparison of IC50 values and Hill slope coe⁄cients (in brackets) at oocyte-expressed K7 and K3L4 receptors and the assumed corresponding
receptors in intracardiac ganglia
K-Conotoxin Oocytes Intracardiac ganglion Reference
K7 (nM) K3L2 (nM) K3L4 (nM) K7* (nM) K3L2*/K3L4* (nM)
EpI 30 (1.1) ^ ^ Inactive at 100 1.6 this study, [6]
[Y15]EpI 118 (1.0) ^ ^ inactive at 100 0.4 this study, [6]
nAuIB ^ ^ 966 (1.1) ^ 1.2 this study, [5]
rAuIB ^ ^ 27,500 (1.1) ^ 0.1 this study, [5]
Fig. 2. Comparison of activity of native and ribbon AuIB at K3L4
nAChRs expressed in Xenopus oocytes. Oocytes were injected with
cRNA encoding K3 and L4 subunits and voltage clamped 2^10 days
after injection. Responses to 100 WM ACh after 5 min incubation in
the presence of peptide are shown as percentage of control re-
sponses. Error bars are S.E.M. and n=3^5 for each data point.
IC50 values and Hill slope coe⁄cients are summarised in Table 1.
Fig. 3. Activity of EpI and [Y15]EpI on oocyte-expressed nAChRs.
Oocytes were injected with cRNA encoding the indicated subunits
and voltage clamped 2^10 days after injection. Responses to 100
WM nicotine after 3 min incubation in the presence of peptide are
shown as percentage of control responses. Error bars are S.E.M.
and n=3^5 for each data point. IC50 values and Hill slope coe⁄-
cients are summarised in Table 1.
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the L2 subunit could account for the ‘EpI resistance’ of the
native K7 receptor this combination was also tested in oo-
cytes. Despite a strong decrease in the current, coexpression
of the L2 subunit caused no di¡erence in EpI sensitivity (data
not shown).
3.4. Do oocyte-expressed K7 nAChRs have a di¡erent EpI
sensitivity than K7 receptors expressed in mammalian
cells?
The above results suggest that so far unidenti¢ed subunits
or splice [14] variants participate in the formation of EpI-re-
sistant K7* receptors or that the functional properties of the
receptor are modi¢ed in a cell-speci¢c way [13]. Di¡erent
properties of recombinant nAChRs in oocytes and mamma-
lian cells have been reported [4]. Factors that could modify
receptor properties include interactions with proteins such as
adaptor proteins, cytoskeletal elements or other membrane
proteins. Since the oocyte is of non-neuronal origin, interact-
ing proteins might either be absent or not su⁄ciently ex-
pressed to modulate the highly overexpressed nAChRs in oo-
cytes e¡ectively. Alternatively, the di¡erent lipid composition
of the oocyte membrane could in£uence receptor function.
Finally, a di¡erence in maturation and folding events or
post-translational processing between the oocytes and mam-
malian cells could result in di¡erent tertiary structures that
exhibit distinct binding and signal transduction properties.
To exclude the possibility that the observed di¡erences in
EpI sensitivity are due to oocyte-speci¢c modi¢cation of the
K7 receptor, EpI was also tested on the HEK293 derived
TRex-293 cell line stably transfected with a K7/5HT3 chimeric
nAChRs. This chimera represents a common model for the K7
receptor which has been di⁄cult to express as a functional
homopentamer [24]. The IC50 value obtained on these cells
was similar (103 nM) to that obtained on oocyte-expressed
receptors (Fig. 4). This small di¡erence can be explained by
di¡erent measuring protocols, toxin application systems and
di¡erent stock solutions. Another explanation would be that
the rat K7 receptor could be slightly more sensitive to EpI
than the chicken isoform used for construction of the chimera.
3.5. Comparison of the activities of EpI and other K-conotoxins
In this study, EpI has been identi¢ed as a potent and se-
lective inhibitor of the recombinant K7 nAChRs as well as the
K7/5HT3 chimera. In this respect, EpI has closest similarity to
the 3/4K-conotoxin ImI with which it also shares the ¢rst eight
amino acids. Interestingly, ImI seems to have a di¡erent bind-
ing mode than the 4/7K-conotoxins [25,26]. However, EpI also
shows a consensus sequence found in the second loop of many
4/7K-conotoxins [10]. Comparison with the other 4/7K-cono-
toxins (Table 2) supports the previously found importance of
a long hydrophobic side chain in position 10 for K7 selectivity
and might indicate that EpI shares a common binding mode
with these 4/7K-conotoxins rather than with ImI. Very re-
cently, the 3/4K-conotoxin ImII, which has nine out of 12
amino acids in common with ImI, was identi¢ed [27]. ImII
inhibits the K7 receptor with similar activity as ImI and EpI
but, in contrast to these, does not compete with K-BTX bind-
ing, indicating that it binds to a di¡erent binding site. Thus
the similar peptides ImI, ImII and EpI seem to represent
important key structures to study the di¡erent binding modes
and binding sites of neuronal active K-conotoxins.
In conclusion, this study con¢rms that subunit combina-
tions in native tissues are much more complex than assumed
and/or that the pharmacology of nAChR receptors might be
modulated by factors other than subunit stoichiometry and
assembly. Understanding the cause of the observed di¡erences
between heterologously expressed and native nAChRs is cru-
cial for future studies that use heterologous expression sys-
tems to identify selective ligands for the characterisation of
native receptors. A thorough comparison and characterisation
of various K-conotoxins in di¡erent systems is therefore essen-
tial to prove the utility of the oocyte system and the validity
of correlations based on the characterisation of oocyte-ex-
pressed subunit combinations. Nevertheless, the activity data
obtained from oocyte-expressed receptors provide an exten-
sive and valuable basis for structure activity studies.
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